Reviews in cardiovascular medicine最新文献

{"title":"P2Y₁₂ Inhibitor Monotherapy in Coronary Artery Disease: Translating Evidence Into Practice.","authors":"Felice Gragnano, Vincenzo De Sio, Arturo Cesaro, Paolo Calabrò","doi":"10.31083/RCM44440","DOIUrl":"10.31083/RCM44440","url":null,"abstract":"","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"26 9","pages":"44440"},"PeriodicalIF":1.3,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12516737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145293421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association Between Body Roundness Index and Cardiovascular Disease Risk: An Analysis Based on the CHARLS Database.","authors":"Yazhao Sun, Pei Sun, Jianfeng Liu, Shiwei Cui, Yongle Li, Yuanyuan Zuo","doi":"10.31083/RCM39048","DOIUrl":"10.31083/RCM39048","url":null,"abstract":"<p><strong>Background: </strong>The body roundness index (BRI) offers a more precise evaluation of body fat and visceral fat levels. However, studies on the relationship between BRI and the risk of cardiovascular disease (CVD) remain limited.</p><p><strong>Methods: </strong>Survival differences across BRI quartiles were estimated using Kaplan-Meier analysis. The association between the BRI and the risk of CVD was examined through Cox proportional hazards and restricted cubic spline (RCS) models. Additional subgroup and sensitivity analyses were also conducted.</p><p><strong>Results: </strong>This study included 6401 patients (47.43% male), with an incidence of CVD of 17.51%. Kaplan-Meier survival analysis revealed statistically significant differences between groups based on the assigned BRI quartiles. Cox models revealed a strong association between the BRI and CVD risk, while RCS models showed a non-linear link between higher BRIs and increased CVD risk. In certain subgroups, an elevated BRI was closely correlated with an increased incidence of CVD. Notable interactions were found between BRI and gender, age, hypertension, diabetes, alcohol consumption, and smoking status. Sensitivity analysis excluding early CVD cases yielded consistent results.</p><p><strong>Conclusion: </strong>A significant non-linear association was found between the BRI and CVD risk. The BRI could be a valuable and sensitive marker for identifying individuals at high risk of CVD, with varying predictive value across different population subgroups.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"26 9","pages":"39048"},"PeriodicalIF":1.3,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12516779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145293446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy and Safety of Echocardiography Versus Radiation Guidance in Percutaneous Balloon Mitral Valvuloplasty: A Retrospective Study.","authors":"Ying'ao Zhao, Yiming Yan, Wenchao Li, Ziping Li, Hang Li, Jianing Cui, Junke Chang, Fengwen Zhang, Fang Fang, Qi Li, Wenbin Ouyang, Xiangbin Pan","doi":"10.31083/RCM46811","DOIUrl":"10.31083/RCM46811","url":null,"abstract":"<p><strong>Background: </strong>Percutaneous balloon mitral valvuloplasty (PBMV) is the preferred treatment for selected patients with rheumatic mitral stenosis (MS). Although prior research has established the feasibility and safety of echocardiography-guided PBMV, this study aimed to compare the mid- to long-term clinical outcomes and safety profiles between echocardiography-guided and conventional fluoroscopy-guided approaches.</p><p><strong>Methods: </strong>Consecutive patients who underwent successful PBMV from January 2016 to December 2022 were enrolled. Participants were stratified into two groups based on procedural guidance method: echocardiography-guided and conventional fluoroscopy-guided. The primary outcome of this study was the success of PBMV, and the secondary outcome was a composite of all-cause mortality, reoperation for mitral valve surgery, or repeat PBMV after discharge. Statistical analyses included the Kaplan-Meier survival analysis with log-rank tests and propensity score matching to adjust for confounding factors.</p><p><strong>Results: </strong>A total of 429 patients underwent PBMV, with 71 (16.6%) in the echo-guided group and 358 (83.4%) in the conventional fluoroscopy-guided group. A success rate of 98.6% was demonstrated in the echocardiography-guided group, and 98.9% in the fluoroscopy-guided group after propensity score match (<i>p</i> = 0.84). During follow-up, nine (14.3%) patients in the echo-guided group required surgical intervention, and 13 (10.4%) in the fluoroscopy-guided group; one (1.6%) patient in the echocardiography-guided group and six (4.8%) in the fluoroscopy-guided group died. No significant differences were observed in freedom from re-intervention (<i>p</i> = 0.33) and survival (<i>p</i> = 0.23).</p><p><strong>Conclusions: </strong>For selected patients with rheumatic MS, echocardiography-guided PBMV demonstrated an equivalent mid- to long-term efficacy and safety profile compared to fluoroscopy-guided approaches.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"26 9","pages":"46811"},"PeriodicalIF":1.3,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12516735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145293378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipoprotein(a) as a Predictor of Cardiovascular Risk in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review.","authors":"Azad Mojahedi, On Chen, Hal A Skopicki, Tahmid Rahman, Amirhossein Sadeghian","doi":"10.31083/RCM42784","DOIUrl":"10.31083/RCM42784","url":null,"abstract":"<p><strong>Background: </strong>Despite advancements in treatment, coronary artery disease (CAD) remains a significant global health concern. Although lipoprotein(a) [Lp(a)] is recognized as a crucial cardiovascular risk factor associated with increased risk, the prognostic value of using Lp(a) levels in patients with acute coronary syndrome (ACS) who have undergone percutaneous coronary intervention (PCI) remains debatable. This review aimed to investigate the association between Lp(a) levels and recurrent ischemic events in patients with ACS undergoing PCI.</p><p><strong>Methods: </strong>This systematic review included studies with individuals aged ≥18 years diagnosed with ACS who underwent PCI and had Lp(a) measurements. The included studies were sourced from the PubMed database, with a focus on articles published between January 2020 and January 2025. Keywords related to Lp(a) and cardiovascular diseases were used in the search. Data extraction involved a review of titles and abstracts followed by quality assessment using the QUADAS-2 tool.</p><p><strong>Results: </strong>The final analysis included 10 studies with a combined population of 20,896 patients from diverse regions, including Japan, India, Egypt, China, and South Korea. Key findings indicate that elevated Lp(a) levels are significantly associated with adverse cardiovascular outcomes, including myocardial infarction and mortality, both in hospital and during long-term follow-up.</p><p><strong>Conclusions: </strong>This review highlights Lp(a) as a critical biomarker for predicting recurrent cardiovascular events in ACS patients post-PCI. The consistent correlation between elevated Lp(a) levels and adverse outcomes underscores the necessity of routine monitoring and targeted management of Lp(a) to mitigate residual cardiovascular risk.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"26 9","pages":"42784"},"PeriodicalIF":1.3,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12516750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145293506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Arrhythmic Mitral Valve Prolapse: Potential Impact and Current Evidence.","authors":"Serghei Covantsev, Andia Taghdiri, Anna Bumbu, Natalia Pichugina, Anna Sukhotko","doi":"10.31083/RCM38956","DOIUrl":"10.31083/RCM38956","url":null,"abstract":"<p><p>Mitral valve prolapse (MVP), also known as floppy mitral valve syndrome, systolic click-murmur syndrome, and billowing mitral leaflets, is a developmental anomaly caused when one or two abnormal valve leaflets are displaced into the left atrium below the mitral valve annulus during systole. MVP is observed in 2-3% of patients in the general population and is the leading cause of mitral regurgitation (MR) in developed countries. Overall, MVP is considered a benign developmental anomaly; however, evidence suggests that MVP is associated with sudden cardiac death. Thus, there have been ongoing discussions about the optimal management of this patient group, which includes both pharmacological treatment and surgical interventions. This review aimed to provide an overview of the benign and arrhythmic MVP (AMVP), its diagnostic options, and management possibilities.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"26 9","pages":"38956"},"PeriodicalIF":1.3,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12516773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145293433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Residual Inflammatory and Cholesterol Risk and the Association With Recurrent Cardiovascular Events in East Asian Patients After Percutaneous Coronary Intervention.","authors":"Ang Gao, Tingting Guo, Zhiqiang Yang, Hong Qiu, Runlin Gao","doi":"10.31083/RCM36438","DOIUrl":"10.31083/RCM36438","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The applicability of currently established high-risk inflammatory criteria to East Asian patients is unknown, particularly concerning the hypersensitive C-reactive protein (hs-CRP) cutoff value. In addition, the role of cholesterol and inflammation in determining the prognosis of these patients might shift after the patient accepts lipid-lowering treatments. This study aimed to explore the high-risk hs-CRP cutoff value and compare the prognostic value between inflammation and cholesterol risk in the East Asian population after treatment with percutaneous coronary intervention (PCI).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Post-PCI patients with serial hs-CRP and low-density lipoprotein cholesterol (LDL-C) level measurements were retrospectively enrolled. Major adverse cardiovascular and cerebrovascular events (MACCEs) were defined as a composite of cardiovascular death, non-fatal acute myocardial infarction (AMI), non-fatal stroke, and unplanned coronary revascularization. The association between residual risks and MACCEs was evaluated.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;During a median follow-up of 30.4 months, 403 MACCEs occurred among 2373 patients. The high-risk LDL-C and hs-CRP cutoff values in the present study were set at 1.56 mg/L and 1.80 mmol/L, respectively, based on the results of tertile stratification and restricted cubic spline analysis. The adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of residual cholesterol risk (hs-CRP &lt;1.56 mg/L; LDL-C ≥1.80 mmol/L), residual inflammatory risk (hs-CRP ≥1.56 mg/L; LDL-C &lt;1.80 mmol/L), and residual cholesterol and inflammatory risk (hs-CRP ≥1.56 mg/L; LDL-C ≥1.80 mmol/L) for MACCEs were 1.26 (0.95-1.66), 2.15 (1.57-2.93), and 2.07 (1.55-2.76), respectively. Inflammatory-induced MACCEs were more likely to be associated with the increased risk of non-fatal AMI (HR: 4.48; 95% CI: 2.07-9.73; &lt;i&gt;p&lt;/i&gt; &lt; 0.001), while cholesterol-induced MACCEs were more likely to be associated with the increased risk of non-target vessel revascularization (TVR: HR: 1.60; 95% CI: 1.08-2.37; &lt;i&gt;p&lt;/i&gt; = 0.019). Persistent high inflammatory risk (baseline and follow-up hs-CRP ≥1.56 mg/L) can be a major determinant of MACCEs (adjusted HR: 2.03; 95% CI: 1.64-2.52; &lt;i&gt;p&lt;/i&gt; &lt; 0.001), while persistent high cholesterol risk (baseline and follow-up LDL-C ≥1.80 mmol/L) was not. Serial hs-CRP measurements could produce more predictive values for MACCEs than a single measurement.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Despite statin treatment, residual cholesterol and inflammatory risks persist in post-PCI patients. The high-risk hs-CRP standard may be lower in East Asian patients than their Western counterparts, with a cutoff value of 1.56 mg/L. Inflammation and cholesterol could be major determinants for recurrent cardiovascular events, while hs-CRP seems to be a stronger predictor than LDL-C in post-PCI patients receiving statin therapy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Clinical trial registration: &lt;/strong&gt;Ch","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"26 9","pages":"36438"},"PeriodicalIF":1.3,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12516752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145293497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Histidine-Tryptophan-Ketoglutarate Cardioplegia on Perioperative Prognosis in Surgery Patients for Combined Valvular and Coronary Heart Disease: A Retrospective Study.","authors":"Pengrui Si, Haokai Qin, Xunxun Feng, Kun Hua, Xiubin Yang, Mingyang Zhou","doi":"10.31083/RCM39546","DOIUrl":"10.31083/RCM39546","url":null,"abstract":"<p><strong>Background: </strong>Combined valve and coronary surgery is technically complex, and the prognosis for such patients remains poor. This study aimed to analyze the short-term prognostic effects of histidine-tryptophan-ketoglutarate (HTK) cardioplegia versus 1:4 cold blood (CB) cardioplegia in patients requiring combined valve and coronary surgery.</p><p><strong>Methods: </strong>This retrospective cohort study categorized patients undergoing valve surgery combined with coronary artery bypass grafting (CABG) into two groups: the HTK group (n = 504) and the CB group (n = 188), based on the type of cardioplegia used. Propensity score matching (PSM) was employed to adjust for baseline differences between the groups. The primary endpoints included operative mortality, postoperative myocardial infarction (PMI), postoperative acute kidney injury (AKI), and postoperative atrial fibrillation (POAF). Secondary endpoints included stroke incidence, ventilation time, aortic cross-clamp time, and intensive care unit (ICU) length of stay (LOS).</p><p><strong>Results: </strong>After PSM, patients with HTK experienced significantly lower rates of AKI and POAF (<i>p <</i> 0.05). Troponin I (TnI) and creatine kinase-MB (CK-MB) measurements at 48 and 72 hours postoperatively were lower in the HTK group compared with the CB group (<i>p <</i> 0.05). However, no significant difference in PMI incidence was detected (<i>p =</i> 0.368). Additionally, the HTK group demonstrated shorter mechanical ventilation times (<i>p =</i> 0.01) and ICU stays (<i>p =</i> 0.009).</p><p><strong>Conclusions: </strong>HTK cardioplegia reduced postoperative ventilation time, ICU LOS, and the incidence of AKI and POAF compared with CB cardioplegia in patients undergoing valve surgery combined with CABG. HTK cardioplegia is effective, safe, and superior to CB cardioplegia in improving short-term outcomes in these patients.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"26 9","pages":"39546"},"PeriodicalIF":1.3,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12516746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145293484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commotio Cordis in Sudden Cardiac Death in the Young: A State-of-the-Art Review.","authors":"Cecilia Salzillo, Andrea Marzullo","doi":"10.31083/RCM43357","DOIUrl":"10.31083/RCM43357","url":null,"abstract":"<p><p>Commotio cordis is a rare but fatal cause of sudden cardiac death in young people, particularly athletes exposed to non-penetrating chest trauma. Commotio cordis occurs when an impact to the chest triggers a lethal ventricular arrhythmia in the absence of pre-existing structural heart disease. Despite advances in the understanding of commotio cordis, the prevention and management of this condition remain challenging. The literature indicates that commotio cordis is most common in adolescents and sports such as baseball, football, and ice hockey. The key pathogenic mechanism involves a chest impact occurring during a vulnerable phase of the cardiac cycle, leading to ventricular fibrillation. Immediate cardiopulmonary resuscitation and prompt use of an automated external defibrillator are crucial for survival. However, the effectiveness of preventive measures, such as chest protectors and greater awareness of cardiovascular emergencies, remains debated. As a leading cause of sudden death in young athletes, commotio cordis requires further research to refine prevention strategies and improve outcomes. This review provides an updated overview of the pathophysiological mechanisms, risk factors, intervention strategies, and preventive approaches for this condition.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"26 9","pages":"43357"},"PeriodicalIF":1.3,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12516778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145293323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Perioperative Recombinant Human Brain Natriuretic Peptide in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis.","authors":"Juanjuan Shao, Liangshan Wang, Chengcheng Shao, Yan Wang, Jin Li, Jianfeng Luo, Zhongtao Du, Xiaotong Hou","doi":"10.31083/RCM36423","DOIUrl":"10.31083/RCM36423","url":null,"abstract":"<p><strong>Background: </strong>Clinical trials have demonstrated the efficacy of recombinant human brain natriuretic peptide (rhBNP) in managing acute decompensated heart failure. Moreover, since rhBNP performs roles in hemodynamic regulation, neurohormonal balance, and renal function, rhBNP administration could benefit cardiac surgery patients. We conducted a systematic review and meta-analysis to evaluate the impact of perioperative rhBNP in cardiac surgery patients.</p><p><strong>Methods: </strong>We conducted a comprehensive search of the MEDLINE, Embase, the Cochrane Library, CNKI, and WANFANG databases from January 1, 2007, until December 31, 2023, identifying randomized controlled trials (RCTs) that examined the use of rhBNP during cardiac surgery. We estimated the treatment effects of perioperative rhBNP administration using a random-effects meta-analysis. The primary cardiovascular endpoint was the change in left ventricular ejection fraction (LVEF); meanwhile, renal function was assessed using the 24-hour urine output, changes in estimated glomerular filtration rate (eGFR), and serum creatinine (SCr) levels. Additional parameters included pulmonary artery pressure (PAP), adverse event (AE) incidence, respiratory support duration, ICU length of stay (ICU LOS), hospital length of stay (hospital LOS), and tumor necrosis factor-α (TNF-α) levels.</p><p><strong>Results: </strong>Our meta-analysis included 38 RCTs encompassing 2280 patients. The use of rhBNP in the perioperative period significantly enhanced LVEF compared to the control group (mean difference = 3.13 (95% CI [1.88, 4.37]; <i>p</i> < 0.00001). Additionally, rhBNP administration was associated with a significant increase in the 24-hour urine volume (mean difference = 401.42, 95% CI [253.06, 549.77]; <i>p</i> < 0.00001) and an improvement in eGFR (mean difference = 13.94, 95% CI [5.57, 22.31]; <i>p</i> = 0.001). Meanwhile, perioperative administration of rhBNP significantly reduced SCr levels (mean difference = -14.55, 95% CI [-22.04, -7.06]; <i>p</i> < 0.0001). In addition, rhBNP significantly decreased PAP, the incidence of AEs, the duration of respiratory support, ICU LOS, hospital LOS, and TNF-α levels.</p><p><strong>Conclusions: </strong>These findings underscore the potential benefits of rhBNP as a perioperative treatment in patients undergoing cardiac surgery.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"26 9","pages":"36423"},"PeriodicalIF":1.3,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12516758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145293441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cuproptosis and Cardiovascular Diseases: Mechanisms, Pathophysiology, and Therapeutic Strategies-A Narrative Review.","authors":"Zhongkai Wang, Changyong Wu, Ruijie Li, Huang Sun, Menghan Li, Yihua Luo, Suli Bao, Yunzhu Peng","doi":"10.31083/RCM38833","DOIUrl":"10.31083/RCM38833","url":null,"abstract":"<p><p>Despite recent efforts and improvements in terms of diagnosis and treatment, cardiovascular diseases (CVDs) remain a prime risk factor for mortality globally; thus, elucidating novel mechanisms underlying the development of these diseases remains essential. There have been significant contributions to identifying the classical means of programmed cell death (PCD), such as apoptosis, necroptosis, pyroptosis, and autophagy, in CVDs. In comparison, although the role of cuproptosis in CVDs is relatively unknown, cuproptosis has recently been revealed as a distinct type of copper-induced cell death with a unique molecular signature and regulation compared to conventional forms of PCD. Thus, cuproptosis represents a novel approach for treating CVDs. To investigate such implications in this review, we will systematically study the cellular mechanisms of cuproptosis and its pathophysiological roles in various forms of CVD. Finally, based on such mechanistic knowledge and to bridge mechanistic research with clinical applications, we propose the use of therapeutic strategies such as copper chelation, antioxidant modalities, and ferredoxin 1 (FDX1)/lipoic acid synthetase (LIAS)-based biomarkers.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"26 9","pages":"38833"},"PeriodicalIF":1.3,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12516759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145293343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}